Nuvation Bio
Update in progressNUVB (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Nuvation Bio is a clinical-stage biopharmaceutical company focused on cancer therapies. Its lead candidate, IBTROZI (taletrectinib), is a ROS1 inhibitor for ROS1-positive non-small cell lung cancer. The company is also advancing Safusidenib, an IDH1-mutant inhibitor in phase 3 trials for maintenance therapy in high-risk IDH1-mutant astrocytoma versus placebo. Founded in 2018 and based in New York City.
Company score
- Sentiment
- 0.40
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE (NYQ)
- LocationUnited States
- CEODr. David T. Hung M.D.
- Founded2018
- Employees305
- Websitewww.nuvationbio.com
Identifiers
- ISINUS67080N1019
- FIGIBBG00VHJ0CC1
- CUSIP67080N101
- CIK0001811063